MATRIX METALLOPROTEINASE-2 (MMP-2 )
AND-9 (MMP-9) GENE VARIANTS AND MICROVASCULAR
COMPLICATIONS IN TYPE 2 DIABETES PATIENTS
Andjelic Jelic M٭ˡ, Radojkovic D², Nikolic A², Rakicevic Lj², Babic T², Jelic D³, Lalic NM⁴
*Corresponding Author: Marina Andjelic Jelic, Department of Endocrinology, Diabetes and Metabolic
Diseases, Clinical Medical Centre Zvezdara, Dimitrija Tucovica 161, 11000 Belgrade, Serbia, Phone +381 64 122 2010 Fax +381 11 3088733, E mail: drmajelic@gmail.com
page: 6
|
|
REFERENCES
1. IDF Diabetes Atlas Ninth edition 2019.
2. Callaghan BC, Price RS, Feldman EL. Distal Symmetric
Polyneuropathy: A Review. JAMA. 2015; 314:
2172–2181.
3. Afkarian M, et al. Clinical Manifestations of Kidney
Disease among US Adults with Diabetes, 1988-
2014. JAMA. 2016; 316: 602–610.
4. Lee R, Wong TY, Sabanayagam C. Epidemiology
of diabetic retinopathy, diabetic macular edema and
related vision loss. Eye Vis (Lond). 2015; 2-17.
5. Doria A. Genetics of Diabetes Complications. Curr
Diab Rep. 2010; 10(6): 467–475.
6. Negase H, Woessnsner JF Jr. Matrix metalloproteinases.
J Biol Chem. 1999; 274:21491-21494.
7. Nikolaos P, Kadoglou, Daskalopoulou S, Perrera D,
Liapis C. Matrix Metalloproteinases and Diabetic Vascular
Complications. Angiology. 2005; 56: 173–189.
8. Kowluru RA, Mishra M. Regulation of Matrix Metalloproteinase
in the Pathogenesis of Diabetic Retinopathy.
Prog Mol Biol Transl Sci. 2017; 148: 67-85.
9. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy.
N Engl J Med Overseas Ed. 2012; 366:1227-39.
10. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence
and major risk factors of diabetic retinopathy.
Diabetes Care. 2012; 35: 556–564.
11. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy.
Lancet. 2010; 376: 124–36.
12. Diabetes Control and Complications Trial Research
Group.The relationship of glycemic exposure
(HbA1c) to the risk of development and progression
of retinopathy in the Diabetes Control and Complications
Trial. Diabetes. 1995; 44: 968–983.
13. Jerneld B, Algvere P. Relationship of duration and
onset of diabetes to prevalence of diabetic r.tinopathy.
Am. J. Ophtalmol. 1986; 102: 431–437.
14. Matthews DR, Stratton IM, Aldington SJ, Holman
RR, Kohner EM. Risks of progression of retinopathy
and vision loss related to tight blood pressure control
in type 2 diabetes mellitus UKPDS 69. Arch. Ophthalmol.
2004; 122(11): 1631–1640.
15. Simó-Servat O, Hernández O, Simó R. Genetics in
diabetic retinopathy: Current Concepts and New Insights.
Curr Genomics. 2013; 14(5): 289–299.
16. Giebel S, Menicucci G, Mc Guire PG, Das A. Matrix
metalloproteinases in early diabetic retinopathy and
their role in alteration of blood – retinal barrier. Lab
Invest. 2005; 85: 567-607.
17. Mohammad G, Kowluru RA. Matrix metalloproteinase
-2 in the development of diabetic retinopathy and
mitochondrial dysfunction. Lab Invest. 2010; 90(9):
1365-1372.
18. Grant MB, Caballero S, Tarnuyyer RW, Bass KE,
Ljubinkov AV, Spoerri PE, Galardy RE. Matrix metalloproteinase
expression in human retinal microvascular
cells. Diabetes. 1998; 47: 1311-7.
19. Salzmann J, Limb GA, Khaw PT, Gregor Z, Webster
L, Chignell AH, Charteris D. Matrix metalloproteinase
and their natural inhibitors in fibrovascular
membranes of proliferative diabetic retinopathy. Br
J Ophtalmo. 2000; 84: 1091-6.
20. Singh K, Goyal P, Singh M, Deshmukh S, Upadhyay
D, Kant S, Agrawal NK, Gupta SK, Singh K. Association
of functional SNP-1562C>T in MMP-9 promoter
with proliferative diabetic retinopathy in north Indian
type 2 diabetes mellitus patients. J Diabetes Complications.
2017; 31(12): 1648-1651.
21. Beranek M, Kolar P, Tschoplova S, Kankova K, Vasku
A. Genetic variations and plasma levels of gelatinase
A (matrix metalloproteinase-2 ) and gelatinase B
(matrix metalloproteinase-9) in proliferative diabetic
retinopathy. Molecular Visio. 2008; 14: 1114-1121. 22. Singh R, Kishore L, Kaur N: Diabetic peripheral
neuropathy: current perspective and future directions.
Pharmacol Res. 2014; 80: 21–35.
23. Argoff CE, Cole BE, Fishbain DA, et al. Diabetic
peripheral neuropathic pain: clinical and quality-oflife
issues. Mayo Clin Proc. 2006; 81(4): S3–11.
24. Jann S, Bramerio MA, Beretta S, Koch S, Defanti
CA, et al. Diagnostic value of sural nerve matrix
metalloproteinase-9 in diabetic patients with CIPD.
Neurology. 2003; 61: 1607-1610.
25. Kuhad A, Singh P, Chopra K. Matrix metalloproteinases:
potential therapeutic target for diabetic neuropathic
pain. Expert Opin Ther Targets. 2015; 19(2):
177-85.
26. Deng X, Ma P, Wu M, Liao H, Sung XJ. Role of
matrix metalloproteinases in myelin abnormalities
and mechanical allodynia in rodents with diabetic
neuropathy. Aging Dis. 2021; 12(7): 1808-1820.
27. Singh K, Agrawal NK, Gupta SK, Singh K. A functional
single nucleotide polymorphism -1562C>T in
the matrix metalloproteinase-9 promoter is associated
with type 2 diabetes and diabetic foot ulcers. Int J
Low Extrem Wounds. 2013; 12(3): 199-204.
28. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic
kidney disease: a report from an ADA Consensus
Conference. Diabetes care. 2014; 37: 2864-2883.
29. United States Renal Data System. Annual Data Report:
Epidemiology of Kidney Disease in the United
States. Bethesda, MD, National Institutes of Health,
National Institute of Diabetes and Digestive and Kidney
Diseases. 2016.
30. Maeda S, Haeda M, Guo B, et al. Dinucleotide repeat
polymorphism of matrix metalloproteinase-9 gene
is associated with diabetic nephropathy. Kidney Int.
2001; 60: 1428-1434.
31. Shalaby, K., Bahriz, R., Mahsoub, N. et al. Matrix
metalloproteinase-9 gene polymorphism (-1562 C/T)
and its correlation with diabetic nephropathy. Egypt
J Intern Med. 2021; 33: 7.
32. Feng S, Ye G, Bai S, Wei H, Liao X, Li L. Matrix
Metalloproteinase-9 -1562C/T Gene Polymorphism
Is Associated with Diabetic Nephropathy. Biomed
Res Int. 2016; 1627143.
33. Gantala SR, Kondapalli MS, Kummari R, Padala
C, Tupurani MA, et al. Collagenase-1 (-1607
1G/2G), Gelatinase-A (-1306 C/T), Stromelysin-1
(-1171 5A/6A) functional promoter polymorphisms
in risk prediction of type 2 diabetic nephropathy.
Gene. 2018; 673: 22-31.
34. Behrforouz A, Dastgheib SA, Abbasi H, Karimi-
Zarrchi M, Javaheri A, Hadadan A, Tabatabaei RS,
Meibodi B, Neamatzadeh H. Association of MMP-
2, MMP-3 and MMP-9 polymorhisms with susceptibility
to recurrent pregnancy loss. Fetal Pediatr
Pathol. 2021; 40(5): 378-386.
35. Sarray S, Dallel M, Lamine LBj Jairajpuri D, Sellami
N et al. Association of matrix metalloproteinase-2
gene polymorphism with susceptibility to type 2
diabetesː A case control study. J Diabetes Complications.
2021; 35(6): 107908.
|
|
|
|
 |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
|
